The Citizens Life Sciences Conference 2026
Logotype for Avanos Medical Inc

Avanos Medical (AVNS) The Citizens Life Sciences Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Avanos Medical Inc

The Citizens Life Sciences Conference 2026 summary

11 Mar, 2026

Strategic execution and business transformation

  • Streamlined operations with a cost takeout in December and divested two underperforming assets, focusing on core segments.

  • Acquired Nexus Medical, strengthening the Specialty Nutrition segment and aligning with the strategy of targeted, synergistic acquisitions.

  • Specialty Nutrition and Pain Management & Recovery are the primary growth engines, with emphasis on mid-single-digit organic growth and annual acquisitions.

  • Successfully mitigated tariff exposure by relocating syringe production from China to Mexico and Cambodia, expecting tariff benefits by 2027.

  • Ongoing cost efficiency initiatives and continued focus on operating improvements beyond one-time events.

Financial performance and outlook

  • Exceeded 2025 revenue and EPS guidance, providing momentum for 2026 with mid-single-digit growth targets.

  • 2026 guidance incorporates $12 million in incremental tariffs, offset by pricing actions and cost savings, supporting earnings expansion.

  • Long-term target of $1 billion revenue by 2030, driven by organic growth and approximately $100 million in acquisitions.

  • Confidence in achieving EPS guidance of $1 for 2026, with tariff headwinds managed through price increases and operational savings.

  • Additional annualized savings of $15–$20 million expected from recent cost initiatives.

Segment and product highlights

  • Specialty Nutrition: NICU/Neonatal Solutions, long-term, and short-term feeding businesses all projected for mid- to high-single-digit growth.

  • CORTRAK and MIC-KEY products maintain market leadership, with next-generation MIC-KEY launch expected by year-end.

  • Short-term feeding segment identified as the largest opportunity for upside due to low market penetration of guided tube placement.

  • Neonatal Solutions, bolstered by Nexus, serves as a platform for further M&A and portfolio expansion.

  • Exploring adjacent opportunities in NICU, including breast milk management, medication delivery, and feeding pumps.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more